Metagenomi Therapeutics (MGX) Price to Sales (2024 - 2026)

Metagenomi Therapeutics (MGX) has reported Price to Sales for 3 consecutive years, with 40.42 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Price to Sales rose 228.13% year-over-year to 40.42 in Q1 2026; TTM through Mar 2026 was 2.26, a 101.12% increase from a year earlier, with the FY2025 full-year figure at 2.42, down 6.41% from the prior year.
• Price to Sales was 40.42 for Q1 2026 at Metagenomi Therapeutics, up from 15.58 in the prior quarter.
• Over five years, Price to Sales peaked at 40.42 in Q1 2026 and troughed at 6.53 in Q2 2025.
• A 3-year average of 14.87 and a median of 12.32 in 2025 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales plunged 38.36% in 2025 and soared 228.13% in 2026, its largest moves.
• Over 3 years, Price to Sales stood at 14.05 in 2024, then gained by 10.91% to 15.58 in 2025, then jumped by 159.4% to 40.42 in 2026.
• The last three Price to Sales figures came in at 40.42 (Q1 2026), 15.58 (Q4 2025), and 10.28 (Q3 2025), per Business Quant data.